Since immunotherapy can be proposed alone or in combination with first-line chemotherapy in patients whose tumors are wild type for EGFR, ALK, ROS1, and BRAF, it is obligatory to obtain the PD-L1 status of tumor cells [7]. Here, BRAF is linked to neoplasm.